Acasti Pharma
225 Promenade du Centropolis
Suite 200
Laval
Quebec
H7T 3B3
Canada
Tel: 450-687-2262
Fax: 450-687-2272
191 articles about Acasti Pharma
-
Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture Exchange
3/13/2023
Acasti Pharma Inc. a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced that it has applied and received approval for a voluntary delisting of its common shares from the TSX Venture Exchange.
-
Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare Conference
3/8/2023
Acasti Pharma Inc. today announced Jan D'alvise, CEO, will present and host one-on-one meetings with investors at the Oppenheimer 33rd Annual Healthcare Conference, held virtually and taking place on March 13-15, 2023.
-
Acasti Pharma Recognizes Rare Disease Day
2/28/2023
Acasti Pharma Inc., a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, recognizes and celebrates Rare Disease Day, as established by the European Organization for Rare Diseases.
-
Acasti Pharma Reports Third Quarter 2023 Operational Results
2/14/2023
Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced financial and operational results for the third quarter ended December 31, 2022
-
Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023
2/7/2023
Acasti Pharma Inc. today announced that it will host a conference call at 1:00 PM Eastern Time on Tuesday, February 14, 2023, to discuss the Company's corporate progress and other developments, as well as financial results for third quarter 2023 ended December 31, 2022.
-
Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule
1/25/2023
Acasti Pharma Inc. announces that it has received notification from the NASDAQ Listing Qualifications Department ("NASDAQ") that it is eligible for an additional 180 calendar days, or until July 24, 2023, to regain compliance with the minimum $1.00 per share requirement.
-
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
1/24/2023
Acasti Pharma Inc. announced Jan D’Alvise, CEO, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.
-
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
1/13/2023
Acasti Pharma Inc. today announced Jan D’alvise, CEO, will present and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 18-19, 2023.
-
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
1/5/2023
Acasti Pharma Inc. today announced that it will host a conference call on Tuesday, January 10, 2023 at 4:30 p.m. ET to review the recently reported preliminary topline results from two separate Phase 1 pharmacokinetic (PK) studies for GTX-101 and GTX-102.
-
Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
12/28/2022
Acasti Pharma Inc., a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announces that the preliminary topline results of the pharmacokinetic bridging study for GTX-102 met all outcome measures.
-
Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)
12/22/2022
Acasti Pharma Inc. today announced that preliminary topline results for its single-dose, pharmacokinetic (PK) bridging study to evaluate the relative bioavailability of GTX-101 compared to the reference listed drug in the U.S., bupivacaine subcutaneous injectable, met all primary outcome measures for the study.
-
Acasti Pharma Reports Second Quarter 2023 Operational Results
11/14/2022
Acasti Pharma Inc. today announced financial and operational results for the second quarter ended September 30, 2022.
-
Acasti Pharma to Present at Q4 Investor Summit
11/9/2022
Acasti Pharma Inc., a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced that Jan D’Alvise, President and CEO of Acasti Pharma will be presenting virtually at the Q4 Investor Summit.
-
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022
11/7/2022
Acasti Pharma Inc. announced that it will host a conference call at 1:00 PM Eastern Time on Monday, November 14, 2022, to discuss the Company’s corporate progress and other developments, as well as financial results for second quarter 2023 ended September 30, 2022.
-
Acasti Announces Court Dismissal of Stockholder Litigation
9/30/2022
Acasti Pharma Inc. announced today that a U.S. court has dismissed the remaining stockholder litigation filed in connection with the Company’s acquisition of Grace Therapeutics, Inc. (“ Grace ”) via merger in August 2021 (the “ Merger ”).
-
Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders
9/29/2022
Acasti Pharma Inc. announced the voting results from its Annual General and Special Meeting of Shareholders which was held virtually on Wednesday September 28, 2022.
-
Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference
9/14/2022
Acasti Pharma Inc. announced today that it will be participating in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.
-
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
9/13/2022
Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces the initiation of its planned pharmacokinetic (PK) bridging study to evaluate the comparative bioavailability, pharmacokinetics, and safety of its oral betamethasone spray, GTX-102, compared to an intramuscular injection of betamethasone and to an oral solution of betamethasone, in 48 healthy subjects.
-
Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
9/12/2022
Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced that management will virtually participate at the H.C. Wainwright 24th Annual Global Investment Conference September 12-16, 2022.
-
Acasti Pharma Reports First Quarter 2023 Operational Results
8/11/2022
Acasti Pharma Inc., a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, announced financial and operational results for the first quarter ended June 30, 2022.